Merck's Backbone Is Cardiovascular, Infectious Disease After Pipeline Integration
This article was originally published in The Pink Sheet Daily
Executive Summary
Merck's late-stage pipeline includes more than 40 compounds in Phase II and Phase III development after combining with Schering-Plough's assets.
You may also be interested in...
Merck Infectious Disease Head Touts Diversity Of Post-Schering Merger Anti-Infective Portfolio
BOSTON – Merck & Co.'s purchase of Schering-Plough created probably the most broad and comprehensive pipeline of anti-infective agents in the industry, according to Roger Pomerantz, Merck's senior vice president and global franchise head, infectious diseases.
Merck Infectious Disease Head Touts Diversity Of Post-Schering Merger Anti-Infective Portfolio
BOSTON – Merck & Co.'s purchase of Schering-Plough created probably the most broad and comprehensive pipeline of anti-infective agents in the industry, according to Roger Pomerantz, Merck's senior vice president and global franchise head, infectious diseases.
Merck Cuts 8 Research, 8 Manufacturing Sites As Part Of Schering Integration
With Schering-Plough integration under way, Merck will phase out research and manufacturing operations in effort to achieve $3.5 billion in savings by 2012.